Positive Results for Masimo

Masimo Corporation (MASI - Analyst Report) recently announced positive results form its 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. Results indicated that continuous pulse oximetry monitoring and clinician notification in post-surgical patients on the general floor leads to a significant drop in key clinical outcome measures, such as 65% fewer rescue events, 48% fewer ICU transfers and reduced annualized ICU time by 135 days.
 
Masimo Patient SafetyNet combines the performance of Masimo SET pulse oximetry at the point of care with remote monitoring and wireless clinician notification via pager. This is the first study on adults using Masimo SET pulse oximetry technology that demonstrated improved patient safety while reducing the cost. 

Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), etc. Masimo SET pulse oximetry eliminates the need to draw blood and wait for results. This helps physicians to immediately detect and treat potentially fatal conditions. 

Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. Hypoxemia, low blood-oxygen levels, can cause brain damage and death. Hyperoxemia, high-blood oxygen levels, can permanently damage eyes and cause blindness. Masimo is a leader in the pulse oximetry monitoring equipment market. The company's closest competitors are Haemonetics Corp. (HAE - Analyst Report) and Becton, Dickinson and Co. (BDX - Analyst Report).

Read the full analyst report on MASI

Read the full analyst report on HAE

Read the full analyst report on BDX